BCLI — Brainstorm Cell Therapeutics Inc.

Summary of BCLI Q2 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: Approximately $2.9 million or $0.34 per share for Q2 2025, compared to a net loss of $2.5 million or $0.60 per share in Q2 2024.
• Research and Development Expenditures: $1.1 million for Q2 2025, up from $0.9 million in Q2 2024.
• General and Administrative Expenses: Decreased to approximately $1.4 million from $2.1 million in the same period last year.
• Cash Position: Approximately $1 million in cash, cash equivalents, and restricted cash as of June 30, 2025.

2. Strategic Updates and Business Highlights

• Phase IIIb Trial: The company is preparing to initiate the ENDURANCE trial for NurOwn in early-stage ALS patients, having received FDA clearance under a Special Protocol Assessment (SPA).
• Manufacturing Partnerships: Secured a partnership with Minaris Advanced Therapies to enhance U.S.-based manufacturing capabilities, complementing an existing collaboration with Pluri Inc. in Israel.
• Citizens Petition: A coalition of ALS patients filed a petition requesting the FDA to review data supporting NurOwn, which Brainstorm supports as a means to potentially expedite access to the treatment.

3. Forward Guidance and Outlook

• Trial Initiation: The company aims to begin the Phase IIIb trial as soon as funding is secured, which is currently a priority.
• Regulatory Pathways: The outcome of the Citizens petition could influence funding opportunities and the potential for accelerated approval pathways, which would be beneficial for advancing the trial.
• Long-term Vision: Brainstorm emphasizes NurOwn's potential beyond ALS, with ongoing research into other neurodegenerative diseases.

4. Bad News, Challenges, or Points of Concern

• NASDAQ Compliance: The company transitioned from NASDAQ to OTCQB due to noncompliance with minimum shareholder equity requirements, which poses challenges for raising capital.
• Funding Difficulties: The inability to secure a significant funding round has delayed the initiation of the Phase IIIb trial. The filing of the Citizens petition has led to a cautious approach from potential investors.
• Regulatory Uncertainty: The evolving regulatory landscape and the need for a comprehensive review of existing data may introduce additional delays or complications in the approval process.

5. Notable Q&A Insights

• Trial Timeline: Management indicated readiness to initiate the Phase IIIb trial but highlighted that funding is a critical barrier.
• Nondilutive Funding: The company faced challenges in applying for nondilutive funding due to timing issues and the inability to demonstrate sufficient co-funding.
• Regulatory Engagement: The FDA's response to the Citizens petition is crucial, with potential implications for the approval process and funding opportunities.
• Survival Data Discussion: Management emphasized the significance of long-term survival data from the expanded access program, which could support the case for NurOwn's efficacy.
• Focus on ALSFRS: The FDA currently considers ALSFRS scores as the primary endpoint for trials, despite discussions on the need for alternative measures.

Overall, while Brainstorm Cell Therapeutics is making progress with its clinical initiatives and regulatory engagements, it faces significant challenges related to funding and compliance that could impact its operational timelines and strategic objectives.